- Filed
- Feb 20, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 10
What Idexx Laboratories's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Launched AI-powered IDEXX inVue Dx cellular analyzer in late 2024
The launch of this new point-of-care analyzer automates cytology and blood cell morphology, representing a significant investment in AI, advanced optics, and cloud-integrated hardware.
AIcloud
Launched IDEXX ImageVue DR50 Plus imaging system in North America in Jan 2026
This new diagnostic imaging system combines high-definition, AI-powered imaging with a lower radiation dose, indicating investment in advanced hardware, AI software development, and go-to-market efforts in North America.
AI
Expanding Cancer Dx Panel internationally and adding new detection capabilities in 2026
IDEXX is launching its canine lymphoma test internationally in H1 2026 and adding mast cell tumor detection in North America, signaling significant investment in global go-to-market strategies, regulatory approvals, and R&D.
Recurring diagnostic revenue now accounts for 79% of consolidated revenue
The company's business model is heavily focused on its durable and profitable recurring revenue from consumables, subscriptions, and services, which reached 79% of total revenue in 2025.
79%
Recurring diagnostic revenue as a percentage of consolidated revenue for the year ended December 31, 2025
SaaS
Investing heavily in AI capabilities across its diagnostic and software platforms
IDEXX is embedding proprietary AI into its core products, including analyzers (SediVue Dx, inVue Dx), decision support (DecisionIQ), and imaging software (Web PACS).
AIcloud
Expanding portfolio of cloud-based SaaS platforms including ezyVet, Animana, and IDEXX Neo.
IDEXX is heavily reliant on cloud technology for its core practice management systems (ezyVet, Animana, Neo), patient workflow (SmartFlow), and imaging (Web PACS).
cloudSaaSezyVetAnimana
Supporting on-premises 'Cornerstone' software while pushing new cloud-based SaaS systems.
IDEXX maintains a significant on-premises software user base with its Cornerstone system while strategically shifting towards cloud-based offerings like ezyVet and Neo.
cloudSaaSon-premisesCornerstone
Acquired reference labs are diluting profitability and may take several years to become profitable.
The company's M&A strategy for reference labs negatively impacts operating margins in the short-term, as acquired labs operate less profitably than the existing network.
IDEXX's gross margins are structurally challenged by the mix of products sold.
Water quality business growth depends on international sales and European regulatory approvals
IDEXX explicitly states that future growth for its Water segment relies on expanding international sales and navigating a complex regulatory approval process, particularly in Europe.
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Idexx Laboratories with the Signal API
One POST /v1/companies/enrich call with idexx.com returns Idexx Laboratories 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"idexx.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Idexx Laboratories 10-K
When did Idexx Laboratories file its latest 10-K?
What does Idexx Laboratories's latest 10-K say about product launch?
Where can I find Idexx Laboratories's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .